Bv8/prokineticin 2 is involved in Aβ-induced neurotoxicity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Severini, Cinzia ^a,b   Lattanzi, Roberta ^c   Maftei, Daniela ^c   Marconi, Veronica ^c   Ciotti, Maria Teresa ^a   Petrocchi Passeri, Pamela ^a   Florenzano, Fulvio ^b   Del Duca, Ester ^b   Caioli, Silvia ^d,e   Zona, Cristina ^d,e   Balboni, Gianfranco ^f   Salvadori, Severo ^g   Nistico, Robert ^b,d   Negri, Lucia ^c  

^a CNR   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^f UNIVERSITY OF CAGLIARI   (Italy)

^g UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); G PROTEIN COUPLED RECEPTOR; GASTROINTESTINAL HORMONE; NEUROPEPTIDE; PEPTIDE FRAGMENT; PROK2 PROTEIN, RAT;

ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HIPPOCAMPUS; LONG TERM POTENTIATION; MALE; METABOLISM; MOUSE; NERVE CELL; PROTEIN TRANSPORT; RAT; TRANSGENIC MOUSE; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; GASTROINTESTINAL HORMONES; GENE EXPRESSION REGULATION; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MICE; MICE, TRANSGENIC; NEURONS; NEUROPEPTIDES; PEPTIDE FRAGMENTS; PROTEIN TRANSPORT; RATS; RECEPTORS, G-PROTEIN-COUPLED; UP-REGULATION;

EID: 84945218780     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15301     Document Type: Article

References (58)

1. Huang, Y., Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222 (2012).
2. Haass, C., Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (2007).
3. Klein, W. L. Synaptotoxic amyloid-? oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease. J Alzheimers Dis. 33, 49-65 (2013).
4. Selkoe, D. J. Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr. Opin. Neurobiol. 4, 708-716 (1994).
5. Mrak, R. E., Griffin, W. S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 26, 349-354 (2005).
6. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (2000).
7. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015 (2006).
8. Heneka, M. T., O'Banion, M. K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184, 69-91 (2007).
9. Sudduth, T. L., Schmitt, F. A., Nelson, P. T., Wilcock, D. M. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol. Aging 34, 1051-1059 (2013).
10. Luster, A. D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338, 436-445 (1998).
11. Hesselgesser, J., Horuk, R. Chemokine and chemokine receptor expression in the central nervous system. J. Neurovirol. 5, 13-26 (1999).
12. Asensio, V. C., Campbell, I. L. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. 22, 504-12 (1999).
13. Rubio-Perez, J. M., Morillas-Ruiz, J. M. A review: inflammatory process in Alzheimer's disease, role of cytokines. Scientific World Journal 2012, 756357 (2012).
14. Mines, M., Ding, Y., Fan, G. H. The many roles of chemokine receptors in neurodegenerative disorders: emerging new therapeutical strategies. Curr. Med. Chem. 14, 2456-2470 (2007).
15. Mollay, C. et al. Bv8, a small protein from frog skin, and its homolog from snake venom induce hyperalgesia in rats. Eur. J. Pharmacol. 374, 189-196 (1999).
16. Kaser, A., Winklmayr, M., Lepperdinger, G., Kreil, G. The AVIT protein family. Secreted cysteine-rich vertebrate proteins with diverse functions. EMBO J. 4, 469-473 (2003).
17. Negri, L. et al. Biological activities of Bv8 analogues. Br. J. Pharmacol. 146, 625-632 (2005).
18. Giannini, E. et al. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci USA 106, 14646-14651 (2009).
19. Negri, L., Lattanzi, R., Giannini, E., Melchiorri, P. Bv8/prokineticin proteins and their receptors. Life Sci. 81, 1103-1116 (2007).
20. Cheng, M. Y., Leslie, F. M., Zhou, Q. Y. Expression of prokineticins and their receptors in the adult mouse brain. J. Comp. Neurol. 498, 796-809 (2006).
21. Negri, L., Lattanzi, R. Bv8-prokineticins and their receptors: modulators of pain. Curr. Pharm. Biotechnol. 12, 1720-1727 (2011).
22. Maftei, D. et al. Controlling the activation of the Bv8/prokineticin system reduces neuroinflammation and abolishes thermal and tactile hyperalgesia in neuropathic animals. Br. J. Pharmacol. 171, 4850-4865 (2014).
23. LeCouter, J., Zlot, C., Tejada, M., Peale, F., Ferrara, N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci USA 101, 16813-8 (2004).
24. Dorsch, M. et al. PK1/EG-VEGF induces monocyte differentiation and activation. J. Leukoc. Biol. 78, 426-434 (2005).
25. Abou-Hamdan, M. et al. Critical role for prokineticin 2 in CNS autoimmunity. Neurol. Neuroimmunol. Neuroinflamm. 2, e95 (2015).
26. Cheng, M. Y. et al. Prokineticin 2 is an endangering mediator of cerebral ischemic injury. Proc Natl Acad. Sci USA 109, 5475-80 (2012).
27. Lattanzi, R. et al. Prokineticin 2 upregulation in the peripheral nervous system has a major role in triggering and maintaining[ neuropathic pain in the chronic constriction injury model. Biomed. Res. Int. in press, doi: 10.1155/2014/301292 (2014b).
28. Balducci, C. et al. The -secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alzheimers Dis. 24, 799-816 (2011).
29. Jacobsen, J. S. et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103, 5161-5166 (2006).
30. Cleary, J. P. et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 8, 79-84 (2005).
31. Crews, L., Masliah, E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum. Mol. Genet. 19, R12-20 (2010).
32. Hardy, J., Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
33. Nistico, R., Pignatelli, M., Piccinin, S., Mercuri, N. B., Collingridge, G. Targeting synaptic dysfunction in Alzheimer's disease therapy. Mol. Neurobiol. 46, 572-587 (2012).
34. Cacquevel, M., Lebeurrier, N., Cheenne, S.& Vivien, D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 5, 529-534 (2004).
35. Finch, C. E., Morgan, T. E. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr. Alzheimer Res. 4, 185-189 (2007).
36. Cooper, N. R., Bradt, B. M., O'Barr, S., Yu, J. X. Focal inflammation in the brain: role in Alzheimer's disease. Immunol. Res. 21, 159-65 (2000).
37. Meda, L., Baron, P., Scarlato, G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol. Aging. 22, 885-893 (2001).
38. Johnstone, M., Gearing, A. J., Miller, K. M. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol. 93, 182-193 (1999).
39. Smits, H. A. et al. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 127, 160-8 (2002).
40. Severini, C. et al. Bindarit, inhibitor of CCL2 synthesis, protects neurons against Amyloid--induced toxicity. J. Alzheimers Dis. 38, 281-293 (2013).
41. Balboni, G. et al. Triazine compounds as antagonists at Bv8-prokineticin receptors. J. Med. Chem. 51, 7635-7639 (2008).
42. Lattanzi, R. et al. Halogenated triazinediones behave as antagonists of PKR1: in vitro and in vivo pharmacological characterization. IJPRS 5, 5064-5072 (2014a).
43. Congiu, C. et al. A new convenient synthetic method and preliminary pharmacological characterization of triazinediones as prokineticin receptor antagonists. Eur. J. Med. Chem. 81, 334-340 (2014).
44. Melchiorri, D. et al. The mammalian homologue of the novel peptide Bv8 is expressed in the central nervous system and supports neuronal survival by activating the MAP kinase/PI-3-kinase pathways. Eur. J. Neurosci. 13, 1694-702 (2001).
45. Urayama, K. et al. Prokineticin receptor-1 induces neovascularization and epicardial-derived progenitor cell differentiation. Arterioscler. Thromb. Vasc. Biol. 28, 841-849 (2008).
46. Soga, T. et al. Molecular cloning and characterization of prokineticin receptors. Biochim. Biophys. Acta. 1579, 173-179 (2002).
47. Negri, L. et al. Nociceptive sensitization by the secretory protein Bv8. Br. J. Pharmacol. 137, 1147-1154 (2002).
48. Negri, L., Lattanzi, R., Giannini, E., Melchiorri, P. Modulators of pain: Bv8 and prokineticins. Curr. Neuropharmacol. 4, 207-15 (2006).
49. Farfara, D., Lifshitz, V., Frenkel, D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J. Cell. Mol. Med. 12, 762-780. 2008.
50. Ben Achour, S., Pascual, O. Glia: the many ways to modulate synaptic plasticity. Neurochem Int. 57, 440-445 (2010).
51. Wu, J., et al. Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency. Neurobiol. Aging. 34, 2843-2852 (2013).
52. Xiong, Y. C. et al. Prokineticin 2 suppresses GABA-activated current in rat primary sensory neurons. Neuropharmacology 59, 589-594 (2010).
53. Ren, P. et al. Prokineticin 2 regulates theelectrical activity of rat suprachiasmatic nuclei neurons. PLoS One. 6(6) e20263 (2011).
54. Ingves, M. V., Ferguson, A. V. Prokineticin 2 modulates the excitability of area postrema neurons in vitro in the rat. Am J Physiol Regul Integr Comp Physiol. 298, 617-626 (2010).
55. Frozza, R. L. et al. Neuroprotective effects of resveratrol against A administration in rats are improved by lipid-core nanocapsules. Mol. Neurobiol. 47, 1066-1080 (2013).
56. Campolongo, P. et al. Systemic administration of substance P recovers beta amyloid-induced cognitive deficits in rat: involvement of Kv potassium channels. PLoS One. 8, e78036 (2013).
57. Pieri, M. et al. SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels. Neuropharmacology. 58, 268-76 (2010).
58. Nistico, R. et al. Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLoS One 8, e54666 (2013).